{"id":5158,"date":"2020-10-11T21:18:14","date_gmt":"2020-10-11T19:18:14","guid":{"rendered":"https:\/\/golivertx.com\/?p=5158"},"modified":"2021-03-19T21:46:56","modified_gmt":"2021-03-19T20:46:56","slug":"goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema","status":"publish","type":"post","link":"https:\/\/golivertx.com\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema\/","title":{"rendered":"GOLIVER THERAPEUTICS LAUR\u00c9ATE DE L\u2019APPEL \u00c0 PROJETS  \u00ab\u00a0PLAN DE RELANCE POUR L\u2019INDUSTRIE &#8211; SECTEURS STRAT\u00c9GIQUES\u00a0"},"content":{"rendered":"<p>03\/2021: GOLIVER THERAPEUTICS LAUR\u00c9ATE DE L\u2019APPEL \u00c0 PROJETS\u00a0 \u00ab PLAN DE RELANCE POUR L\u2019INDUSTRIE &#8211; SECTEURS STRAT\u00c9GIQUES \u00bb POUR SON PROJET DE PLATEFORME DE BIOPRODUCTION INDUSTRIELLE, AVEC \u00c0 LA CL\u00c9, UN BIOM\u00c9DICAMENT \u00c0 PARTIR DE CELLULES SOUCHES.<\/p>\n<p>\u279e Communiqu\u00e9 de presse : <a href=\"https:\/\/golivertx.com\/wp-content\/uploads\/2021\/03\/GoLiver_CP_Subvention_France_Relance_20210318.pdf\">GoLiver_CP_Subvention_France_Relance_20210318<\/a><\/p>\n<p><u>\u279e <a href=\"https:\/\/www.latribune.fr\/entreprises-finance\/industrie\/chimie-pharmacie\/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html\">https:\/\/www.latribune.fr\/entreprises-finance\/industrie\/chimie-pharmacie\/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html<\/a><\/u><\/p>\n<p>\u279e<a href=\"https:\/\/www.lesechos.fr\/pme-regions\/innovateurs\/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316\">https:\/\/www.lesechos.fr\/pme-regions\/innovateurs\/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316<\/a><\/p>\n<p>\u279e <a href=\"https:\/\/nantes.maville.com\/actu\/actudet_--medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm\">https:\/\/nantes.maville.com\/actu\/actudet_&#8211;medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm<\/a><\/p>\n<p>\u279e <a href=\"https:\/\/biotechinfo.fr\/article\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance\/\">https:\/\/biotechinfo.fr\/article\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>11\/2020: GoLiver Therapeutics a re\u00e7u le <b>Sceau d&rsquo;Excellence de la Commission Europ\u00e9enne<\/b> dans le cadre de Horizon H2020-EIC Accelerator. Apr\u00e8s seulement 3 ans de cr\u00e9ation, cela montre l&rsquo;importance de notre projet (crit\u00e8res d\u2019Excellence, Impact et Mise en \u0153uvre) au niveau de l&rsquo;UE et constitue un nouveau gage de garantie de la qualit\u00e9 et du potentiel de d\u00e9veloppement de notre soci\u00e9t\u00e9 aupr\u00e8s de ses investisseurs actuels et futurs, des fonds publics et priv\u00e9s et des autres acteurs<i>. Merci beaucoup \u00e0 tous les Centres de greffe de foie,\u00a0 aux Pharma, aux Institutions publiques et aux Associations de patients qui nous ont donn\u00e9 une lettre d&rsquo;int\u00e9r\u00eat, et f\u00e9licitations \u00e0 la belle \u00e9quipe<\/i>!<\/p>\n<p>\u279e<a href=\"https:\/\/golivertx.com\/wp-content\/uploads\/2021\/03\/Sceau-dExcellence-de-la-Commission-Europeenne-.jpg\"> https:\/\/golivertx.com\/wp-content\/uploads\/2021\/03\/Sceau-dExcellence-de-la-Commission-Europeenne-.jpg<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>06\/2020: GoLiver Therapeutics obtient un avis scientifique positif de l\u2019Agence europ\u00e9enne du m\u00e9dicament (EMA)<br \/>\nsur sa strat\u00e9gie de d\u00e9veloppement clinique et de bioproduction dans l\u2019insuffisance h\u00e9patique aigu\u00eb<br \/>\n\u279e <a href=\"https:\/\/www.atlanpolebiotherapies.com\/actualites\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament\/\">https:\/\/www.atlanpolebiotherapies.com\/actualites\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament\/<\/a><br \/>\n\u279e <a href=\"https:\/\/biotechinfo.fr\/article\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance\/\">https:\/\/biotechinfo.fr\/article\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance\/<\/a><br \/>\n\u279e <a href=\"https:\/\/www.aphp.fr\/contenu\/lap-hp-et-goliver-therapeutics-signent-un-protocole-daccord-pour-mettre-en-place-des-essais\">https:\/\/www.aphp.fr\/contenu\/lap-hp-et-goliver-therapeutics-signent-un-protocole-daccord-pour-mettre-en-place-des-essais<\/a><br \/>\n\u279e <a href=\"http:\/\/www.cadureso.com\/actualite\/industrie-de-la-sante\/11490-2020-06-17-12-53-15\">http:\/\/www.cadureso.com\/actualite\/industrie-de-la-sante\/11490-2020-06-17-12-53-15<\/a><br \/>\n\u279e <a href=\"https:\/\/www.businesswire.com\/news\/home\/20200629005030\/en\/GoLiver-Therapeutics-Receives-a-Positive-Scientific-Advice-from-the-European-Medicines-Agency-EMA-on-its-Clinical-Development-and-Biomanufacturing-Strategy-for-Acute-Liver-Failure\">https:\/\/www.businesswire.com\/news\/home\/20200629005030\/en\/GoLiver-Therapeutics-Receives-a-Positive-Scientific-Advice-from-the-European-Medicines-Agency-EMA-on-its-Clinical-Development-and-Biomanufacturing-Strategy-for-Acute-Liver-Failure<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>12\/2019: GoLiver Therapeutics signe un protocole d&rsquo;accord avec l\u2019ho\u0302pital Paul Brousse, premier centre de greffe de foie en France pour de\u0301marrer des essais cliniques de phase 1\/2a<br \/>\npour le traitement des insuffisances he\u0301patiques se\u0301ve\u0300res<br \/>\n\u279e <a href=\"https:\/\/www.atlanpole.fr\/wp-content\/uploads\/2019\/12\/CP_GoLiver_20191205_VDEF.pdf\">https:\/\/www.atlanpole.fr\/wp-content\/uploads\/2019\/12\/CP_GoLiver_20191205_VDEF.pdf<\/a><br \/>\n\u279e <a href=\"https:\/\/www.aphp.fr\/actualite\/lap-hp-et-goliver-therapeutics-signent-un-protocole-daccord-pour-mettre-en-place-des\">https:\/\/www.aphp.fr\/actualite\/lap-hp-et-goliver-therapeutics-signent-un-protocole-daccord-pour-mettre-en-place-des<\/a><br \/>\n\u279e <a href=\"https:\/\/www.thepharmaletter.com\/article\/goliver-seeks-regenerative-alternative-to-liver-transplantation\">https:\/\/www.thepharmaletter.com\/article\/goliver-seeks-regenerative-alternative-to-liver-transplantation<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>12\/2019: Le Monde News. Dans les biotechnologies et la sant\u00e9, le \u00ab jeu \u00e0 la nantaise \u00bb fait \u00e9clore des p\u00e9pites.<\/p>\n<p>\u279e <a href=\"https:\/\/www.lemonde.fr\/campus\/article\/2019\/12\/14\/dans-les-biotechnologies-et-la-sante-le-jeu-a-la-nantaise-fait-eclore-des-pepites_6022843_4401467.html\">https:\/\/www.lemonde.fr\/campus\/article\/2019\/12\/14\/dans-les-biotechnologies-et-la-sante-le-jeu-a-la-nantaise-fait-eclore-des-pepites_6022843_4401467.html<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>09\/2019: Laur\u00e9at \u00ab French Tech Seed \u00bb (Bpifrance DeepTech)<br \/>\n\u279e <a href=\"https:\/\/www.atlanpole.fr\/actualites\/le-consortium-french-tech-seed-pays-de-la-loire-labellise\/\">https:\/\/www.atlanpole.fr\/actualites\/le-consortium-french-tech-seed-pays-de-la-loire-labellise\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>07\/2019: Publication scientifique. Fourrier A et al. Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells. Xenotransplantation. 2020 Jan;27(1):e12544.<br \/>\n\u279e <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31342573\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31342573\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>05\/2019: GoLiver Therapeutics pr\u00e9sent \u00e0 BIO-Europe Spring et anime une session sur le NASH ( \u201cWhat\u2019s NEXT in NASH?)<br \/>\n\u279e <a href=\"https:\/\/www.atlanpolebiotherapies.com\/actualites\/goliver-therapeutics-a-lhonneur-a-bioeurope-spring\/\">https:\/\/www.atlanpolebiotherapies.com\/actualites\/goliver-therapeutics-a-lhonneur-a-bioeurope-spring\/<\/a><br \/>\n\u279e <a href=\"https:\/\/www.labiotech.eu\/in-depth\/nash-treatment\/\">https:\/\/www.labiotech.eu\/in-depth\/nash-treatment\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>03\/2019: GoLiver Therapeutics GoLiver Therapeutics identifi\u00e9e parmi les 100 start-up o\u00f9 investir par le Magazine Challenges<br \/>\n\u279e \u00a0<a href=\"https:\/\/www.challenges.fr\/classements\/start-up\/2019\/\">https:\/\/www.challenges.fr\/classements\/start-up\/2019\/<\/a><br \/>\n\u279e \u00a0<a href=\"https:\/\/www.challenges.fr\/start-up\/goliver-reparer-le-foie-sans-greffe_648605\">https:\/\/www.challenges.fr\/start-up\/goliver-reparer-le-foie-sans-greffe_648605<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>02\/2019: Laur\u00e9at France Tech Transfer Invest (FFTI) Tech Tour<br \/>\n\u279e<a href=\"https:\/\/www.atlanpole.fr\/actualites\/goliver-therapeutics-laureat-biotech-de-la-france-tech-transfer-invest-2019\/\"> https:\/\/www.atlanpole.fr\/actualites\/goliver-therapeutics-laureat-biotech-de-la-france-tech-transfer-invest-2019\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>12\/2018: Subvention FEDER de l\u2019Union Europ\u00e9enne pour r\u00e9ussir les premi\u00e8res \u00e9tapes de l\u2019industrialisation de son proc\u00e9d\u00e9 de bioproduction (2018-2020).<\/p>\n<p>&nbsp;<\/p>\n<p>01\/2018: Publication scientifique. Kilens S, et al. Parallel derivation of isogenic human primed and naive induced pluripotent stem cells. Nat Commun. 2018 Jan 24;9(1):360.<br \/>\n\u279e <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29367672\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29367672\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>12\/2015: Publication scientifique. Tolosa L, Caron J, Hannoun Z, Antoni M, L\u00f3pez S, Burks D, Castell JV, Weber A, Gomez-Lechon MJ, Dubart-Kupperschmitt A. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther. 2015 Dec 12;6:246.<br \/>\n\u279e <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26652177\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/26652177\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>03\/2021: GOLIVER THERAPEUTICS LAUR\u00c9ATE DE L\u2019APPEL \u00c0 PROJETS\u00a0 \u00ab PLAN DE RELANCE POUR L\u2019INDUSTRIE &#8211; SECTEURS STRAT\u00c9GIQUES \u00bb POUR SON PROJET DE PLATEFORME DE BIOPRODUCTION INDUSTRIELLE, AVEC \u00c0 LA CL\u00c9, UN BIOM\u00c9DICAMENT \u00c0 PARTIR DE CELLULES SOUCHES. \u279e Communiqu\u00e9 de presse : GoLiver_CP_Subvention_France_Relance_20210318 \u279e https:\/\/www.latribune.fr\/entreprises-finance\/industrie\/chimie-pharmacie\/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html \u279ehttps:\/\/www.lesechos.fr\/pme-regions\/innovateurs\/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316 \u279e https:\/\/nantes.maville.com\/actu\/actudet_&#8211;medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm \u279e https:\/\/biotechinfo.fr\/article\/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance\/ &nbsp; 11\/2020: GoLiver Therapeutics a [&hellip;]\n","protected":false},"author":1,"featured_media":4670,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[215],"tags":[],"_links":{"self":[{"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/posts\/5158"}],"collection":[{"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/comments?post=5158"}],"version-history":[{"count":5,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/posts\/5158\/revisions"}],"predecessor-version":[{"id":5219,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/posts\/5158\/revisions\/5219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/media\/4670"}],"wp:attachment":[{"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/media?parent=5158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/categories?post=5158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/golivertx.com\/wp-json\/wp\/v2\/tags?post=5158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}